Joseph Pantginis

Wall Street Analysts Say These 5 Stocks Are A Buy As The World Prepares For The Post-COVID-19 Era

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade

Analysts See 100% Upside To Rigel After Tavalisse Approval

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

Analysts See 100% Upside To Rigel After Tavalisse Approval

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies

Joseph Pantginis Recent News

This Strata Skin Analyst Is Modeling For More Than 400% Upside In Stock

Analyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock

Analyst Makes The Case For Ligand As A 'Core' Holding

Cytokinetics Still A Buy After Phase 2 SMA Data

Aptose Upgraded To Buy At Roth, Price Target Doubled

Roth Resumes Coverage On Fibrocell With Buy Rating, $7 Target

Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It

Flex Pharma Could Still Double From Here, Roth Analyst Says

Roth Capital's New Buy Rating On TetraLogic: 'SMAC'ing Cancer Around'

Prima BioMed Shares Rally Following New Buy Rating, $6 Target From Roth Capital

Roth Capital Expects Aduro Biotech 'To Shine' Next Year After Meeting Management

No Longer A Buy: Roth Capital Downgrades Keryx Biopharma, Slashes Price Target To $6

Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?

5 Biotech Stocks Roth Capital Analysts Are Watching

Cytokinetics Surges Amid Roth Capital Raising Its Price Target

Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth